About Our Subscribers

The Cancer Letter and The Clinical Cancer Letter reach thousands of professionals in oncology and the pharmaceutical industry. Most subscribers receive the newsletters electronically, as PDF files in their email, or download it online through electronic site licenses with their companies or institutions.

Following is a list of our site license customers whose employees have access to the newsletters online:

• American Society of Clinical Oncology—all headquarters office staff.
  
• Bayer Pharmaceuticals Corp.—West Haven, CT, research and development staff.
  
• Baylor College of Medicine Cancer Center— all staff, including 200 center members.
• Biogen Idec—all staff, about 3,400 employees worldwide.
  
• City of Hope National Medical Center and Beckman Research Institute—all staff.
  
• Dana-Farber Cancer Institute—all staff (about 2,000).
• DFCI/Harvard Cancer Center—center members.
  
• Duke Comprehensive Cancer Center—all staff, including 300 physicians and scientists.
• Fox Chase Cancer Center—all staff.
  
• Genentech Inc.—all staff worldwide.
  
• H. Lee Moffitt Cancer Center & Research Institute—all staff (about 1,654).
• Karmanos Cancer Institute—all staff (about 1,200).
• Pfizer—all staff, inlcuding 13,000 research scientists.
• Roswell Park Cancer Institute—all staff (about 2,400).
• Sanofi-Aventis Inc.—all staff worldwide.
  
• Southwest Oncology Group Operations Office—all staff.
  
• U.S. Army Congressionally Directed Medical Research Programs—about 30 staff.
• University of Colorado Cancer Center—all staff.
  
• University of Kentucky and Lucille P. Markey Cancer Center—entire university has access.
• University of Pittsburgh Cancer Institute—all staff including about 500 faculty.
• U.S. National Cancer Institute—licenses with divisions provide access for several hundred staff.
  

In addition, individuals in the fields of oncology, patient advocacy, law, investment, pharma and biotech, and state and federal government subscribe to The Cancer Letter Inc. publications.

About Our Target Audience

The Cancer Letter— academic or practicing oncologists, drug, device, and biotech company executives and scientists, cancer center and hospital administrators, health organizations, patient advocacy groups, and legal, insurance, investment, and other professionals who follow federal regulation and government activities related to cancer research and cancer care.

The Clinical Cancer Letter— oncologists, nurses, other health professionals, pharmaceutical and biotech sales reps, and patients interested in following cancer research results.